New psoriasis drug shows promise in chinese trial

NCT ID NCT06011733

Completed Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 study tested the drug bimekizumab in 133 Chinese adults with moderate to severe plaque psoriasis. Participants received either bimekizumab or a placebo for 16 weeks. The main goals were to see if bimekizumab could clear at least 90% of psoriasis (PASI90) and achieve clear or almost clear skin (IGA 0/1) compared to placebo. The trial is completed, but results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bimekizumab
What this could lead to: If successful, bimekizumab could offer a new treatment option for Chinese adults with moderate to severe plaque psoriasis, helping clear skin and reduce symptoms.
What could go wrong: This is a phase 3 trial, but results are not yet published. As with any drug, side effects are possible, and it may not work for everyone. Long-term safety and effectiveness are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC PLAQUE PSORIASIS MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS

Contacts and locations

Locations

Ps0041 20022

Hangzhou, China
Ps0041 20023

Beijing, China
Ps0041 20117

Guangzhou, China
Ps0041 20120

Wuhan, China
Ps0041 20136

Tianjin, China
Ps0041 20184

Shenzhen, China
Ps0041 20193

Hangzhou, China
Ps0041 20247

Beijing, China
Ps0041 20296

Hangzhou, China
Ps0041 20306

Beijing, China
Ps0041 20308

Shanghai, China
Ps0041 20309

Xi'an, China
Ps0041 20310

Ningbo, China
Ps0041 20311

Guangzhou, China
Ps0041 20312

Jinan, China
Ps0041 20313

Guangzhou, China
Ps0041 20314

Wuxi, China
Ps0041 20318

Jinan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.